Two Made -in -India HPV Test Kit – An essential clinical tool for cervical cancer – AIIMS Delhi doctors rolled out after successful evaluation.

The results of scientific review were announced at a meeting by the Biotechnology Industry Research Assistance Council (Birac).

Evaluation of two HPV Kit-Trubnat HPV-HPV-HPV-HPV-Plus by Goa-based Molibio Diagnostics, and Patho has been launched by the Malayab Discovery Solutions in Pune developed under the Department of Biotechnology, now launched in the market, which is one step ahead to combat the second most common type of cancer among Indian women.

How do indigenous HPV kits work

Newly valid kits use a chip-based real-time real-time PCR (RT-PCR) technology, known for its accuracy and speed.

These kits are designed to detect eight high -risk HPV genotypes, which are responsible for more than 96% of cervical cancer cases globally.

These kits were evaluated by a team of experts from All India Institute of Medical Sciences (AIIMS) New Delhi, National Institute of Cancer Prevention and Research (NICPR) Noida, and National Institute for Research for Research for Research for Reproductive and Child Health (NIRCH) with National Institute in Mumbai Was done with the support of the international agency.

“The main feature of these kits is only seven-eight most common cancer-producing types, which will allow a very efficient and cost-effective screening program, which will be the best for India,” Dr. Neerja Bhatla, former head of the Department of Optitude and Women’s Sciences, AIIM, Dell and Chief Coordinator, PTI.

The set that set these tests is that they have the ability to use them as point-off-care tools, which means they can distribute the results quickly and can also be used in resources-limiting or rural healthcare settings. This is particularly important in India, where access to clinical laboratories can be a major obstacle.

“In view of the growth of RTPCR-based clinical features across the nation in the Kovid era, the introduction of sensitive RTPCR-based HPV test kit can prove to be a cost-effective screening method on classical HPV DNA and PAP smear for deployment in the National Cancer Screening Program,” Dr. Bhatla said.

A public health threat

HPV (human papillomavirus) is a common viral infection that spreads in contact with the skin to the skin, often through sexual contact. According to the World Health Organization (WHO), the virus is so common that almost all sexually active individuals will contract it at some point in their lives. While most HPVs are harmless, some virus variants cause serious health problems, leading to various forms of cancer, including cervical cancer.

Cervical cancer is a serious public health issue in India, which is almost responsible for every four cervical cancer cases globally. Each year, more than 1.23 lakh women are newly diagnosed, and about 77,000 women lose their lives for illness.

What is related to this disease that cervical cancer is prevented. While all cervical cancer cases are not caused by HPV infection, most cases are caused by viruses. Therefore, early and regular screening for HPV can help catch the disease before it becomes fatal.

The WHO has recently recommended that all countries adopt HPV testing as primary screening method. According to the global strategy of the health agency, women should undergo two HPV tests during their lifetime, once at the age of 35 and again at 45.

The target is a screening of 70% eligible women by 2030, which will significantly reduce the deaths due to cervical cancer.

‘One step ahead in preventive care’

Union Minister Dr. Jitendra Singh enhanced preventive healthcare and India’s efforts to become a global leader in this space.

In the event where two med-in-India HPV test kits were designed for quick screening of cervical cancer, Jitendra Singh said that this was the right time to accept India’s growing success in scientific innovation, especially in the health sector.

He cited the development of the world’s first DNA vaccine for Covid-19, which was also created in India in 2021 as a major achievement, which gained international recognition and helped transfer global perceptions.

He said, “India was once seen as a country that was neither a preventive nor healing healthcare focused. The perception is changing,” he said, the country’s first indigenous antibiotics, and a gene therapy test for Hemophilia, were published in New England Journal of Medicine.

He credited these milestones for the joint efforts of public institutions and private companies, describing it as a “entire science and entire government” approach.

Current methods of screening for cervical cancer include visual inspection with acetic acid (through), papanicolau test (PAP test or PAP smear) and HPV DNA tests. Singh said that these tests are expensive and taking time, and are not always enough sensitive.

The new HPV test kits are faster, more inexpensive and suitable for use in remote areas.